(Q33928599)

30 July 2017

1 reference

title

Niacin dosing: relationship to benefits and adverse effects (English)

1 reference

30 July 2017

1 reference

Capuzzi DM

1

1 reference

30 July 2017

Morgan JM

series ordinal

2

1 reference

30 July 2017

Brusco OA Jr

series ordinal

3

1 reference

30 July 2017

Intenzo CM

series ordinal

4

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Current Atherosclerosis Reports

30 July 2017

published in

1 reference

30 July 2017

volume

2

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

64-71

1 reference

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0096-Y

Effects of colestipol-niacin therapy on human femoral atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0096-Y

Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0096-Y

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0096-Y

Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.

21 January 2018

1 reference

12 December 2020

State-of-the-art update and review: clinical trials of lipid-lowering agents

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

12 December 2020

Mechanistic studies of high-density lipoproteins

1 reference

12 December 2020

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

1 reference

12 December 2020

Fluvastatin with and without niacin for hypercholesterolemia

1 reference

12 December 2020

Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial.

1 reference

12 December 2020

Influence of nicotinic acid on serum cholesterol in man.

1 reference

12 December 2020

Use of Niacin as a Drug

1 reference

12 December 2020

A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmityl transferase

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Results of recent large cholesterol-lowering trials and implications for clinical management

1 reference

12 December 2020

Lovastatin, nicotinic acid, and rhabdomyolysis

1 reference

12 December 2020

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia

1 reference

12 December 2020

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Normalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid

1 reference

12 December 2020

Treatment of hyperlipidemia with combined niacin-statin regimens

1 reference

12 December 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

12 December 2020

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.

1 reference

12 December 2020

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease

1 reference

12 December 2020

Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia

1 reference

12 December 2020

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

1 reference

12 December 2020

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 reference

12 December 2020

Differential effects of nicotinic acid in subjects with different LDL subclass patterns

1 reference

12 December 2020

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

1 reference

12 December 2020

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

12 December 2020

The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study

1 reference

12 December 2020

10.1007/S11883-000-0096-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1022736819

0 references

1 reference